A preliminary draft was issued in April, followed by a hearing that brought out several hundred people and heated, often angry, debate.
After a draft guidance is issued by FDA for stakeholders to provide comments on, this objective is to be fully implemented by 2017, using standardized clinical terminology developed by open standards development organizations.
Every draft is thoroughly vetted before it is issued for public comment for a six-week period.
The last draft call was issued in Dec., 1972.
After the draft regulations are issued, there will be a public comment period, and final rules will be issued by Nov. 1, to take effect in July 2011.
A draft rule was issued by the S.E.C. and the other federal financial regulators on Oct. 11, 2011, with a comment period ending in February 2012.
Since the draft recommendations were issued last fall, additional data from the largest American and European P.S.A. screening trials have been published, giving the task force additional evidence on which to make its final recommendations.
In the weeks before the draft rule was issued, Exelon lobbyists attended two other White House meetings, records show, giving it greater White House access than any other company or environmental group trying to influence the outcome.
Draft guidelines were issued last spring; final ones came out in July.
In an interview with a journalist, Peter Collignon, noted that the draft guidelines were issued on the presumption that xenotransplantation was acceptable notwithstanding its public health risks.
